ArticleAdvances in radiation oncology2026
From Clinical Trials to Clinical Practice-Patterns of Practice Survey on Prostate SABR in Australia and New Zealand.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Prostate stereotactic ablative body radiotherapy (SABR) is now a standard-of-care radiation therapy option for prostate cancer based on high-level clinical trial evidence. As part of the Australia and New Zealand (ANZ) prostate SABR guideline development process, the Royal Australian and New Zealand College of Radiologists has commissioned a pattern-of-practice survey on contemporaneous prostate SABR practice. Methods and Materials: We conducted a cross-sectional survey among ANZ genitourinary radiation oncologists (ROs), focusing on patient selection, contouring, treatment planning, and delivery of prostate SABR. Results: A total of 53 ROs across ANZ responded to the survey (response rate: 28%). Of the 41 ROs currently offering prostate SABR, 95%, 90%, 35%, 5%, and 0% offer prostate SABR as standard-of-care options to individuals with favorable intermediate risk, unfavorable intermediate risk, favorable high risk (NINJA/ TROG18.01 trial eligible), very high risk, and node-positive prostate cancer, respectively. Most ROs (86%) routinely use fiducial markers. All ROs routinely request planning magnetic resonance imaging for contouring. Clinical target volume contouring ranged from prostate alone (26%) to prostate plus proximal 1 cm of the seminal vesicles (81%). Planning target volume margins ranged from 3 to 5 mm. An anisotropic 5 mm margin with 3 mm posteriorly was most common (56%). Nineteen (45%) ROs provide a focal boost to the intraprostatic lesion. The most common dose fractionation was 36.25 Gy to the planning target volume and 40 Gy to the clinical target volume over 5 fractions, delivered as 2 (50%) to 3 fractions (76%) per week. The majority of ROs offer prostate SABR on standard computed tomography-linear accelerator (LINAC) (88%), with several ROs also treating patients with CyberKnife (10%) and magnetic resonance-LINAC (5%). Of the ROs who use standard computed tomography-LINAC, 84% use intrafraction motion monitoring. Twelve (23%) ROs do not offer prostate SABR. The main barrier cited was a lack of expertise (42%). Conclusions: This ANZ-wide prostate SABR pattern-of-practice survey demonstrated some variations in practice, providing contemporary insight into how prostate SABR is delivered across ANZ and highlighting barriers to wider adoption.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.